On May 29, 2023 Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, reorted that it is scheduled to give a company presentation on Tuesday, June 6 at the 2023 BIO International Convention taking place in Boston, Massachusetts, between June 5 – 8, 2023 (Press release, Bridge Biotherapeutics, MAY 29, 2023, View Source [SID1234632182]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Pavel Printsev, Director of Business Development, will provide an up-to-date company overview as well as an introduction to its clinical-stage assets:
Oncology: BBT-176 and BBT-207 (Fourth-generation EGFR TKIs for non-small cell lung cancer active against C797S resistance mutations)
Pulmonology: BBT-877 (Autotaxin inhibitor for idiopathic pulmonary fibrosis)
Earlier this year, the company announced its acquisition of a diagnostics company with a novel biosensing technology. The company presentation is expected to include an introduction to the newly acquired biosensing technology and commercial prospects.
"We are pleased to share the progress of clinical assets as well as new business activities through an in-person presentation at this year’s BIO International conference, following last year’s event. We look forward to advancing our novel research and development pipeline with a strong focus on oncology and pulmonology," stated Pavel Printsev, Director of Business Development of Bridge Biotherapeutics.
To learn more about this session, please visit the events page on our website at https://bit.ly/3lEGVDY.
Date & Time: Tuesday, June 6th, 2023, 3:15 PM (ET)
Place: Room 104B
Therapeutic category: Multiple Therapeutics